Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker Tools for Predicting Response to Dostarlimab and Pembrolizumab in Recurrent NSCLC
NCT06405230Phase 2Terminated
- Sponsor
- GSK
- Start
- Oct 2025
- Primary completion
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of dostarlimab, pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by GSK. Started Oct 2025; status: terminated.
02
Drugs
dostarlimabpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06405230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06405230.